Myeloma-Developing Regimens Using Genomics (MyDRUG)

  • STATUS
    Recruiting
  • End date
    Feb 10, 2024
  • participants needed
    228
  • sponsor
    Multiple Myeloma Research Consortium
Updated on 16 September 2021

Summary

The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a greater than 25% mutation to the genes listed can be enrolled to a non-actionable treatment arm.

The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002 study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies. (NCT02884102).

Description

The study will enroll 228 patients enrolled to one of eight treatment arms. The study is open to patients relapsing with relapsed refractory multiple myeloma, who have

  • received at least one prior but no more than 3 prior therapies
  • exposed to both a PI and an IMiD
  • had early relapse after initial treatment. Relapse is defined as the IMWG uniform response criteria (Kumar et al, 2016). Early relapse as defined by at least one of the
    following
    1. Relapse within 3 years post autologous stem cell transplantation (ASCT) on maintenance, or 18 months if unmaintained
    2. Relapse within 18 months of initial non-ASCT based therapy

Details
Condition Relapsed Refractory Multiple Myeloma
Treatment Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide, Erdafitinib, dexamethasone, ixazomib, pomalidomide, Venetoclax, dexamethasone, ixazomib, pomalidomide, Daratumumab, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Selinexor, dexamethasone, ixazomib, pomalidomide
Clinical Study IdentifierNCT03732703
SponsorMultiple Myeloma Research Consortium
Last Modified on16 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Willing to be registered into the pomalidomide (POMALYST) Risk Evaluation and Mitigation Strategy (REMS) program
Enrolled in the MMRF002 Molecular Profiling Protocol (NCT02884102) with report less than 120 days old
Disease free of prior malignancies for 3 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma "in situ" of the cervix or breast, or prostate cancer not requiring therapy
High risk patients with relapsed refractory multiple myeloma (RRMM), who have
received at least one prior but no more than 3 prior therapies
exposed to both a PI and an IMiD
had early relapse after initial treatment Early relapse as defined by at least one of the following: (Relapse is defined as the IMWG uniform response)
Relapse within 3 years of initiation of induction chemo therapy for post autologous stem cell transplantation (ASCT) followed by maintenance, or 18 months if unmaintained after ASCT
Within 18 months of initial non-ASCT based therapy
Patients must have progressed after their most recent treatment and require therapy for myeloma
Females of reproductive potential must have a negative pregnancy test at baseline, be non-lactating, and willing to adhere to scheduled pregnancy testing
Females of reproductive potential and males must practice and acceptable method of birth control
Laboratory values obtained 14 days prior to registration
Absolute neutrophil count (ANC) 1000/ul
Hemoglobin (Hgb) 8 g/dl
Platelet (PLT) 75,000/ul
Total bilirubin <1.5 x upper limit of normal (ULN) or if total bilirubin is >1.5 x ULN, the direct bilirubin must be 2.0 mg/dL
Aspartate aminotransferase (AST) <3 x ULN
Creatinine Clearance 30 mL/min
Measurable disease of Multiple Myeloma (MM) as defined by at least one of the
following
Serum monoclonal protein 0.5 g by protein electrophoresis
mg of monoclonal protein in the urine on 24-hour electrophoresis
Serum immunoglobulin free light chain (FLC) 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio
Monoclonal bone marrow plasmacytosis 30% (evaluable disease)
Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2
Ability to take aspirin, warfarin, or low molecular weight heparin
Sub-Protocol Inclusion Criteria
Refer to each respective Sub Protocol for additional inclusion criteria

Exclusion Criteria

Patients will be ineligible for this study if they meet any one of the
following criteria
Aggressive multiple myeloma requiring immediate treatment as defined by
Lactate dehydrogenase (LDH) > 2 times ULN
Presence of symptomatic extramedullary disease or central nervous system involvement
Hypercalcemia >11.5 mg/dl
Acute worsening of renal function (CrCl < 30 ml/min) directly related to myeloma relapse
Any neurological emergency related to myeloma
Clinical symptoms of hyperviscosity related to monoclonal protein
Involved serum free light chain > 100 mg/dL (1000 mg/L) in the setting of prior diagnosis of cast nephropathy
Infection requiring systemic antibiotic therapy or other serious infection within 14 days of enrolment
Known hypersensitivity or development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide, pomalidomide or similar drug. Known allergy to any of the study medications, their analogues, or excipients in the various formulations of the agents
Prior Ixazomib/Pomalidomide/Dexamethasone combination therapy
Pregnant or breast-feeding females
Serious medical or psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse compliance, interfere in the completion of treatment per protocol, or follow-up evaluation
Active hepatitis A, B or C viral infection or known human immunodeficiency virus (HIV) infection
Concurrent symptomatic amyloidosis or plasma cell leukemia
POEMS syndrome [plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes]
Residual side effects to previous therapy > Grade 1 prior to initiation of therapy (Alopecia any grade and/or neuropathy Grade 2 without pain are permitted)
Prior allogeneic or ASCT within 12 weeks of initiation of therapy. Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD)
Prior experimental therapy within 14 days of protocol treatment or 5 half-lives of the investigational drug, whichever is longer
Prior anticancer therapy within 14 days of initiation of protocol therapy (Dexamethasone/ 40mg/day) for a maximum of 4 days before screening is allowed
Prior major surgical procedure or radiation therapy within 4 weeks of the initiation of therapy (this does not include limited course of radiation used for management of bone pain within 7 days of initiation of therapy)
Known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or Gastro Intestinal (GI) absorption of drugs administered orally
Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months
Other co-morbidity, which would interfere with patient's ability to participate in trial or that confounds the ability to interpret data from the study
Sub-Protocol Exclusion Criteria
Refer to each respective Sub Protocol for additional exclusion criteria
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note